Vaccine therapy in NSCLC: a review

Approximately 200,000 people will develop lung cancer in the USA this year. Roughly 85% of those will die of their disease. Standard chemotherapeutic agents have modestly prolonged survival in this population. The discovery of activating mutations, and their inhibitors has had a more significant impact, but this is limited to the small percentage of the population that harbor the currently known mutations with approved therapeutics. Recent advances in the field of immune checkpoint inhibitors like CTLA4 or PD1 have reinvigorated the interest in immunotherapy. In this review, we will analyze the most significant findings in the field of lung cancer vaccines, and will focus on the different methods of immune activation that attempt to induce a tumor specific response.

Click here to view the full article